Dosage and varietal recommendations for the treatment of medical conditions using cannabis

A method of determining a sensitivity of a subject to one or more cannabinoids, the method comprising:

• testing nucleic acid from the subject to determine the presence or absence of a genetic variant that modifies the expression and/or activity of one or more of the wild-type CYP2C9, CYP3A4, and CYP2C19 genes, wherein the genetic variant comprises any one or more of the genetic variants identified in Tables 1, 2, and 3.

The method of claim 1, further comprising treating the subject for a medical condition with the one or more cannabinoids, wherein the medical condition comprises one or more of anxiety, appetite disorder, depression, inflammation, pain, nausea, vomiting, seizures, and sleep.

A method of determining a sensitivity of a subject to one or more cannabinoids for the treatment of pain, the method comprising:

• testing nucleic acid from the subject to determine the presence or absence of a genetic variant that modifies the expression and/or activity of one or more of the wild-type CYP2C9, CYP3A4, and CYP2C19 genes, wherein the genetic variant comprises any one or more of the genetic variants identified in Tables 15 and 16.